Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
- Brachat A. H.
- Grom A. A.
- Wulffraat N.
- Brunner H. I.
- Quartier P.
- Brik R.
- McCann L.
- Ozdogan H.
- Rutkowska-Sak L.
- Schneider R.
- Gerloni V.
- Harel L.
- Terreri M.
- Houghton K.
- Joos R.
- Kingsbury D.
- Lopez-Benitez J. M.
- Bek S.
- Schumacher M.
- Valentin M. -A.
- Gram H.
- Abrams K.
- Martini A.
- Lovell D. J.
- Nirmala N. R.
- Ruperto N.
- Cuttica R.
- Emminger W.
- Lauwerys B.
- Wouters C.
- Goffin L.
- Sztajnbok F.
- Radominski S.
- Oliveira S.
- Haddad E.
- Kone-Paut I.
- Desjonqueres M.
- Fischbach M.
- Thon A.
- Foell D.
- Weibarth-Riedel E.
- Horneff G.
- Trauzeddel R.
- Berner R.
- Kallinich T.
- Trachana M.
- Constantin T.
- Barash J.
- Berkun Y.
- Uziel Y.
- Corona F.
- Alessio M.
- Cimaz R.
- Viola S.
- Flato B.
- Ferrandiz M.
- Calvo I.
- Anton J.
- Robledillos J. C.
- Gamir M. L.
- Magnusson B.
- Hofer M.
- Unsal E.
- Erguven M.
- Ozen S.
- Wilkinson N.
- Chieng A.
- Ramanan A.
- Foster H.
- Nistala K.
- Higgins G.
- Marzan K.
- Schikler K.
- Morris P.
DOIAbstract
Background: Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). Methods: Gene expression was measured in patients with febrile SJIA and in matched healthy controls by Affymetrix DNA microarrays. Transcriptional response was assessed by gene expression changes from baseline to day 3 using adapted JIA American College of Rheumatology (aACR) response criteria (50 aACR JIA). Changes in pro-inflammatory cytokines IL-6 and IL-18 were assessed up to day 197. Results: Microarray analysis identified 98...
Add to ORKG